Oak Ridge Therapeutic Discovery, LLC

Activating mechanosensing pathways to transform bone and metabolic disease.

ORRxD is developing first-in-class oral small-molecule therapies that target the PC1/PC2 polycystin complex and related pathways with genetically supported roles in skeletal and metabolic health.

Explore our pipeline Investors & partners

Privately held · Preclinical-stage biotechnology company

PC1PC2

Bone formation

Metabolic health

Mechanosensing

Genetically validated biologyA differentiated mechanosensing axis

Oral small moleculesStructure-guided proprietary chemistry

Dual therapeutic potentialBone and metabolic applications

Our science

Turning the body’s mechanical signals into therapeutic opportunities.

The PC1/PC2 polycystin complex helps cells translate mechanical forces into biological responses. ORRxD’s mechanomimetics are designed to activate or stabilize this complex, reproducing beneficial signals associated with skeletal loading and metabolic regulation.

Our discovery approach integrates human genetics, disease biology, structure-guided chemistry and translational pharmacology to advance differentiated oral therapeutics.

01Validated targets

02Structure-guided discovery

03Translational pharmacology

04Candidate development

Preclinical evidence

A differentiated mechanism with bone-anabolic potential.

ORRxD’s foundational MS/MS2 series is designed to stabilize the PC1/PC2 mechanosensing complex. Results shown below are preclinical and do not establish safety or efficacy in humans.

Diagram of the MS2-stabilized PC1 and PC2 heterotetrameric mechanosensing complex — Proposed MS2 molecular-staple model: stabilization of the PC1/PC2 complex is intended to support channel assembly, calcium signaling and downstream osteogenic signaling.

Preclinical mouse study showing effects of MS2 on bone formation in wild-type and PC1 TAZ pathway knockout mice — In wild-type mice, MS2 increased trabecular bone volume and cortical thickness; the response was absent in the compound PC1/TAZ knockout model, supporting a pathway-dependent effect. Xiao & Quarles, *Bone Research* (2023), PMID: 37884491.

Therapeutic context

How the MS/MS2 mechanomimetic program differs from established bone-anabolic approaches

Feature	MS/MS2 mechanomimetics	PTH analogs	Anti-sclerostin antibody
Primary mechanism	PC1/PC2 complex stabilization and activation	PTH1 receptor agonism	Sclerostin inhibition
Modality	Small-molecule research series; oral development objective	Injectable peptide	Injectable monoclonal antibody
Bone evidence	MS2 increased bone volume and cortical thickness in wild-type mice	Clinically validated bone-anabolic class	Clinically validated bone-anabolic class
Metabolic signal	Reduced adiposity and body-weight measures in preclinical mouse studies	Not a primary therapeutic objective	Not a primary therapeutic objective
Direct PC1/PC2 targeting	Yes	No	No
Development status	Preclinical	Approved therapeutic class	Approved therapeutic class

Comparisons describe mechanism, modality and development status; they are not head-to-head efficacy claims. MS2 findings are from animal studies.

Pipeline

A focused portfolio in bone and metabolic disease.

Development stages are estimates and may change as preclinical studies progress.

PC1/PC2 Mechanomimetics

Polycystin mechanosensing complex

Age-related osteoporosis

Obesity and metabolic disease

Lead optimization

DiscoveryIND-enablingClinical

FGF23 Antagonists

FGF23 signaling

Mineral metabolism disorders

Kidney–bone axis

Discovery / preclinical

DiscoveryIND-enablingClinical

GPRC6A Agonists

GPRC6A

Metabolic disease

Diabetes, obesity and fatty liver disease

Discovery / preclinical

DiscoveryIND-enablingClinical

Leadership & advisors

Scientific depth supported by experienced development counsel.

Darryl Quarles, M.D.

Founder & Chief Executive Officer

Professor Emeritus, UTHSC · Adjunct Professor, Duke University

Zhousheng Xiao, M.D., Ph.D.

Scientific Leadership

Inventor and bone–mineral metabolism researcher

Stewart Turner

Strategic Advisor

Company formation and business strategy

Sarah Cork

Intellectual Property Counsel

Life-sciences intellectual property strategy

Tony Polverino, Ph.D.

Drug Development Advisor

Translational and biopharmaceutical development

Investors & strategic partners

Building toward candidate nomination and IND-enabling development.

ORRxD welcomes conversations with investors, pharmaceutical partners and research collaborators interested in differentiated therapies for osteoporosis, obesity and related metabolic disorders.

Start a conversation

Near-term value drivers

Advance PC1/PC2 lead optimization
Confirm translational efficacy and exposure
Complete candidate-enabling CMC and safety planning
Expand strategic and financing partnerships

Contact

Connect with ORRxD.

For investment, partnering, scientific and corporate inquiries.

hq@orrxd.com

5100 Poplar Avenue, Suite 2700 · Memphis, Tennessee 38137